Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT3FLT4KDRKITPDGFRAPDGFRBRET
The experimentally established mechanism targets of Sunitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 16/20 | 0.97 |
| ▸ | PDGFRB known ✓ | P09619 | 7/20 | 0.97 |
| ▸ | CSF1R known ✓ | P07333 | 3/20 | 0.97 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 0.97 |
| ▸ | RET known ✓ | P07949 | 2/20 | 0.97 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.97 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.97 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.97 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.97 |
| ▸ | PRKAA1 | Q13131 | 13/20 | 0.97 |
| ▸ | PRKAA2 | P54646 | 12/20 | 0.97 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.97 |
| ▸ | EGFR | P00533 | 3/20 | 0.97 |
| ▸ | PLK4 | O00444 | 2/20 | 0.97 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.97 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.97 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.97 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.97 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.97 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sunitinib SCHEMBL27843727 | 1.00 | KDR (0.97) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL30314241 | 0.98 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL20805212 | 0.98 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL8082 | 0.98 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL25343938 | 0.98 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL25343935 | 0.98 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL8081 | 0.98 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL2296353 | 0.97 | KDR (0.98) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL23668540 | 0.97 | KDR (0.98) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL28454734 | 0.97 | KDR (0.98) | KDRPRKAA1PRKAA2PDGFRBFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067915-B2 | Sunitinib and salts thereof and their polymorphs | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-06-30 | — | — | US | disclosed |
| US-8618309-B2 | Sunitinib and salts thereof and their polymorphs | TEVA PHARMACEUTICAL INDUSTRIES LTD. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130296575-A1 | SUNITINIB AND SALTS THEREOF AND THEIR POLYMORPHS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-11-07 | — | — | US | disclosed |
| EP-2373642-A2 | PROCESS FOR THE PREPARATION OF SUNITINIB MALATE VIA SUNITINIB ACETATE AND THEIR POLYMORPHS | Teva Pharmaceutical Industries Ltd (IL) | 2011-10-12 | — | — | EP | disclosed |
| US-20110118477-A1 | SUNITINIB AND SALTS THEREOF AND THEIR POLYMORPHS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-05-19 | — | — | US | disclosed |
| WO-2010011834-A2 | SUNITINIB AND SALTS THEREOF AND THEIR POLYMORPHS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296575-A1 | SUNITINIB AND SALTS THEREOF AND THEIR POLYMORPHS | KDR, TP53, FLT1 | KDR 1/4885PDGFRB 43/4885CSF1R 904/4885 |
| US-20110118477-A1 | SUNITINIB AND SALTS THEREOF AND THEIR POLYMORPHS | KDR, TP53, FLT1 | KDR 1/4885PDGFRB 43/4885CSF1R 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.